NewsBenzingaBarclays mantiene la recomendación de sobreponderar sobre Visteon y reduce el precio objetivo a 105 dólares. Barclays mantiene la recomendación de sobreponderar sobre Visteon y reduce el precio objetivo a 105 dólares. Benzinga 2026.10.28 16:11 (GMT+0) Open on Benzinga Other news GE HealthCare Lifts Forecasts on Healthy Hospital Spending Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $35 TD Cowen Maintains Hold on United Parcel Service, Raises Price Target to $116 Truist Securities Maintains Buy on United Parcel Service, Raises Price Target to $120 Truist Securities Maintains Buy on Sensata Technologies, Lowers Price Target to $57 Essex Property Trust Q3 2026 Earnings Call Transcript
